Navigation Links
ChemoCentryx to Present at The 9th World Congress on Inflammation in Tokyo, Japan
Date:7/8/2009

MOUNTAIN VIEW, Calif., July 8 /PRNewswire/ -- ChemoCentryx, Inc. today announced that Thomas J. Schall, Ph.D., ChemoCentryx's President and Chief Executive Officer, will give a keynote lecture at The 9th World Congress on Inflammation in Tokyo, Japan. Dr. Schall's lecture titled, "Treating Inflammation by Inhibition of Chemokine Receptors: Practical Requirements and Efficacy of CCR9 Antagonism in Inflammatory Bowel Disease" will be given on Thursday, July 9, 2009 at 9:00 am local time.

"It is a privilege to have been invited to speak at this prestigious gathering of thought leaders involved in the search for innovative treatments in inflammatory disease," said Thomas J. Schall, Ph.D., ChemoCentryx's President and Chief Executive Officer. "With recent regulatory approvals and clinical trial successes of chemokine-based therapeutics, this underscores the enthusiasm and promise of developing drugs that selectively inhibit specific chemokine and chemoattractant receptors in the treatment of inflammatory diseases."

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a network of secreted chemokine molecules, or ligands, and cell surface receptors that regulates inflammation. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, is in a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease. CCX025, als
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. ChemoCentryx Appoints Edward E. Penhoet, Ph.D., to Board of Directors
2. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
3. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
4. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
5. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
7. AtriCure to Present at Roth Capital Partners 2007 New York Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. MDS to Present at Thomas Weisel Partners Healthcare Conference
10. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
11. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... say knowledge is power, and a new UCLA study has ... men making the best decisions about how to treat their ... well educated about their disease have a much more difficult ... could negatively impact the quality of their care and their ... call for physicians, who can use the findings to target ...
(Date:8/27/2014)... Co-operative Research Centre into Microtechnologies, is coordinating ... innovative solutions based on microtechnologies to tackle ... life sciences, among others. IK4-Ikerlan, Ceit-IK4, IK4-Tekniker, ... with CIC microGUNE on this project, which ... Etortek 2013-2014 programme of the Government of ...
(Date:8/27/2014)... Men who eat over 10 portions a week of ... developing prostate cancer, new research suggests. , With 35,000 ... 10,000 deaths, prostate cancer is the second most common ... developed countries, which some experts believe is linked to ... following dietary and lifestyle recommendations reduces risk of prostate ...
(Date:8/27/2014)... German . There ... tumors. In case of pancreatic cancer, one of the most ... of the patients die within five years after the diagnosis. ... reduce this mortality rate. For preclinical and clinical tests of ... 5 million from investors. This will allow for the further ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Bedros Keuilian is ... in the world, the leading fitness boot camp marketing ... Gym Rescue reality series. One thing he knows very well ... a subject matter expert in the fitness business. , In ... he lays out a step-by-step instructional guide on how fitness ...
Breaking Medicine News(10 mins):Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 2Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 3Health News:Microtechnologies for driving forward mobility and human health 2Health News:Fighting prostate cancer with a tomato-rich diet 2Health News:Preclinical development of tumor therapeutic agent starts 2Health News:Bedros Keuilian Releases New Fitness Boot Camp Marketing Webinar on Building a Personal Brand 2Health News:Bedros Keuilian Releases New Fitness Boot Camp Marketing Webinar on Building a Personal Brand 3
... German . The human brain is the ... their corresponding projections, all woven together in a highly complex, ... practically insurmountable challenge to scientists. Now, however, a research team ... developed a method for tackling the mammoth task. Using two ...
... Alexandria, VA, USA The International and American Associations ... of Dental Research a study that investigated bone ... rare, primary malignant bone tumor that is more prevalent ... whether there is an association between fluoride and risk ...
... molecular medicine and genetics and of immunology and microbiology ... was awarded $1.7 million by the National Institute of ... Institutes of Health to explore how molecular elements in ... disease (NAFLD). The liver is an irreplaceable ...
... The Endocrine Society,s Journal of Clinical Endocrinology & Metabolism ... fructose corn syrup for two weeks as 25 percent of ... and triglycerides, which have been shown to be indicators of ... recommends that people consume only five percent of calories as ...
... This release is available in Spanish . ... finding breast tumors, and appears to increase a woman,s risk ... a large UC Davis study has found. The analysis ... most definitive findings to date on whether the popular mammography ...
... inherited mutations in a gene called HPRT1 lead to ... uncontrollable urges to bite their fingers, slam their arms ... mice with mutations in the same gene don,t behave ... of Medicine have identified a gene related to HPRT1, ...
Cached Medicine News:Health News:The brain's connectome -- from branch to branch 2Health News:The brain's connectome -- from branch to branch 3Health News:Study shows bone fluoride levels not associated with osteosarcoma 2Health News:NIH awards WSU researcher $1.7 million to study non-alcoholic fatty liver disease 2Health News:Fructose consumption increases risk factors for heart disease 2Health News:Popular mammography tool not effective for finding invasive breast cancer 2Health News:Gene gives clues to self-injurious behavior in rare disorder 2
(Date:8/27/2014)... , Aug. 27, 2014 Amgen (NASDAQ: ... Drug Administration (FDA) has granted priority review designation for ... Ivabradine is an oral drug that inhibits the ... sinoatrial node, the body,s cardiac pacemaker. 1 Ivabradine ... on myocardial contractility or ventricular repolarization. 1 Heart ...
(Date:8/27/2014)... -- "Fatty Liver Disease Global Clinical Trials Review, H2, ... trial scenario. This report provides elemental information and data ... Disease . It includes an overview of the trial ... of trial conduction across the globe. The databook offers ... phase, trial status, prominence of the sponsors and also ...
(Date:8/27/2014)... 2014 IRIDEX Corporation (NASDAQ: IRIX ) ... is scheduled to make an investor presentation at the ... Eastern Time on Wednesday, September 3, in New York City.  ... presentation will be available in the Investors section of the ... IRIDEX IRIDEX Corporation was founded in 1989 and ...
Breaking Medicine Technology:FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 2FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 3FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 4FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 5FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 6FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 7Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 2Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 3Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 4Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 5
... New Jersey, April 16, 2012 NoviPet , ... , will showcase new food supplements for dogs at the Backer,s ... take place on April 18-20 2012, in Atlantic City, New Jersey. ... company,s booth 834 at Atlantic City Convention Center. NoviPet intends to ...
... MUMBAI, India, April 15, 2012  Piramal Imaging SA ("Piramal"), ... PIRHEALTH, BSE: 500302], announced positive first results from a ... florbetaben reliably detects beta-Amyloid in the brain during life ... potential tool to aid in the diagnosis and assessment ...
Cached Medicine Technology:NoviPet to Present New Food Supplements for Dogs at Pet Industry Spring Trade Show 2Encouraging Phase III Study Results Show PET Imaging with Florbetaben Reliably Detects Beta-Amyloid in the Brain 2Encouraging Phase III Study Results Show PET Imaging with Florbetaben Reliably Detects Beta-Amyloid in the Brain 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: